Literature DB >> 9000536

Growth-inhibitory and apoptosis-inducing activities of calprotectin derived from inflammatory exudate cells on normal fibroblasts: regulation by metal ions.

S Yui1, M Mikami, K Tsurumaki, M Yamazaki.   

Abstract

We have shown previously that a calcium-binding protein complex, calprotectin, derived from polymorphonuclear leukocytes exerts a cytostatic and cytolytic effect against a very broad range of tumor cell lines. We also described that calprotectin is an apoptosis-inducing factor for certain tumor cells and that zinc ion attenuates the calprotectin activities. The titers of the factor in body fluids are known to increase greatly in various types of inflammation. In this study, to learn the role of calprotectin in inflammation, the growth-inhibitory and the apoptosis-inducing activities of the factor against normal fibroblasts were examined because fibroblasts are a cell type constituting a local inflammatory site. Rat calprotectin inhibited the growth of murine embryonic as well as human dermal fibroblasts. Although calprotectin induced apoptotic morphology in both fibroblasts, the reaction was slower and less efficient than cases using tumor cells as targets. The activities were significantly abrogated by 10-50 microM Zn2+, Cu2+, Mn2+, or Fe2+, respectively, whereas the trivalent cations Al3+ and Fe3+ had no effect. The dose-response curves of the calprotectin effects were shifted to about 10-fold lower concentration ranges in the divalent metal ion-depleted medium. These results suggest that calprotectin extracellularly affects the inflammatory processes by modulating the growth and survival states of normal fibroblasts, and that the effects are physiologically controlled by several metal ions.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9000536

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  21 in total

1.  Loss of myeloid related protein-8/14 exacerbates cardiac allograft rejection.

Authors:  Koichi Shimizu; Peter Libby; Viviane Z Rocha; Eduardo J Folco; Rica Shubiki; Nir Grabie; Sunyoung Jang; Andrew H Lichtman; Ayako Shimizu; Nancy Hogg; Daniel I Simon; Richard N Mitchell; Kevin Croce
Journal:  Circulation       Date:  2011-12-05       Impact factor: 29.690

2.  Expression of calcium-binding proteins MRP8 and MRP14 in inflammatory muscle diseases.

Authors:  Stephan Seeliger; Thomas Vogl; Ingo Hubert Engels; J Michael Schröder; Clemens Sorg; Cord Sunderkötter; Johannes Roth
Journal:  Am J Pathol       Date:  2003-09       Impact factor: 4.307

3.  ANTI-INFECTIVE PROTECTIVE PROPERTIES OF S100 CALGRANULINS.

Authors:  Kenneth Hsu; Chantrakorn Champaiboon; Brian D Guenther; Brent S Sorenson; Ali Khammanivong; Karen F Ross; Carolyn L Geczy; Mark C Herzberg
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-12-04

4.  Inhibition of human papillomavirus type 16 E7 phosphorylation by the S100 MRP-8/14 protein complex.

Authors:  Sharof Tugizov; Jennifer Berline; Rossana Herrera; Maria Elena Penaranda; Mayumi Nakagawa; Joel Palefsky
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

Review 5.  Non-invasive investigation of inflammatory bowel disease.

Authors:  J A Tibble; I Bjarnason
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

6.  The C-terminus of murine S100A9 protein inhibits hyperalgesia induced by the agonist peptide of protease-activated receptor 2 (PAR2).

Authors:  C S Dale; N Cenac; L R G Britto; M A Juliano; L Juliano; N Vergnolle; R Giorgi
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

7.  Calprotectin inhibits matrix metalloproteinases by sequestration of zinc.

Authors:  B Isaksen; M K Fagerhol
Journal:  Mol Pathol       Date:  2001-10

8.  Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseases.

Authors:  A Damms; S C Bischoff
Journal:  Int J Colorectal Dis       Date:  2008-07-16       Impact factor: 2.571

9.  Substitution of methionine 63 or 83 in S100A9 and cysteine 42 in S100A8 abrogate the antifungal activities of S100A8/A9: potential role for oxidative regulation.

Authors:  Herve Y Sroussi; Gerwald A Köhler; Nina Agabian; Dana Villines; Joel M Palefsky
Journal:  FEMS Immunol Med Microbiol       Date:  2008-12-11

10.  S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway.

Authors:  Saeid Ghavami; Iran Rashedi; Brian M Dattilo; Mehdi Eshraghi; Walter J Chazin; Mohammad Hashemi; Sebastian Wesselborg; Claus Kerkhoff; Marek Los
Journal:  J Leukoc Biol       Date:  2008-03-13       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.